Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd (KMDA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products for rare and serious conditions. Its news flow reflects activity across commercial operations, clinical programs, plasma collection, and corporate strategy.
On this page, readers can follow Kamada news related to its proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Company announcements frequently discuss revenue trends, adjusted EBITDA, and guidance, highlighting the contribution of its Proprietary Products and Distribution segments, including biosimilar launches in Israel and supply agreements in markets such as Canada.
News items also cover clinical and post-marketing research, including updates on the InnovAATe Phase 3 trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency and its subsequent discontinuation following an interim futility analysis, as well as the SHIELD study evaluating CYTOGAM in high-risk kidney transplant recipients. Regulatory and operational milestones, such as FDA approval of the Houston, Texas plasma collection center and expansion of plasma collection capacity across Kamada’s three Texas sites, are recurring topics.
Investors and followers of KMDA stock can use this feed to track quarterly and annual financial results, guidance updates, tender awards like the Canadian Blood Services supply extension, and participation in healthcare and investor conferences. Regularly reviewing this page provides a consolidated view of Kamada’s commercial progress, R&D developments, and strategic initiatives as reported in its press releases and related filings.
Kamada (NASDAQ: KMDA) has secured a significant $25 million contract for supplying KAMRAB® and VARIZIG® in Latin America over a three-year period from 2025-2027. This contract with an international organization reinforces Kamada's position in the specialty plasma-derived field.
KAMRAB is used for post-exposure prevention of rabies infection, while VARIZIG is indicated for post-exposure prophylaxis in high-risk individuals for Varicella Zoster. The revenue expected from this contract for 2025 is already included in the company's recently announced revenue guidance.
The agreement demonstrates the global strength of Kamada's specialty immunoglobulin portfolio and supports their multi-year growth outlook. The company plans to pursue additional commercial contracts in key strategic territories beyond the U.S. and Canada.
Kamada (NASDAQ: KMDA) has affirmed its 2024 financial guidance and provided strong growth projections for 2025. The company expects to achieve its 2024 targets of $158-162 million in revenue and $32-35 million in adjusted EBITDA, with year-end cash of $78 million.
For 2025, Kamada forecasts continued double-digit growth with revenue of $178-182 million and adjusted EBITDA of $38-42 million, representing year-over-year increases of 13% and 19% respectively at the mid-point of guidance.
Key strategic initiatives include:
- Pursuing new business development and M&A opportunities
- Expanding plasma collection operations with a third center in San Antonio, TX by Q1 2025
- Reducing the sample size of their Inhaled AAT clinical trial from 220 to 180 patients, with an interim futility analysis planned by end of 2025
Kamada (NASDAQ: KMDA) reported strong Q3 2024 financial results with revenues of $41.7 million, up 10% year-over-year, and nine-month revenues of $121.9 million, up 15%. Q3 Adjusted EBITDA reached $8.8 million, an 11% increase, while nine-month Adjusted EBITDA was $25.4 million, up 43%. The company raised its full-year Adjusted EBITDA guidance to $32-35 million and maintained revenue guidance of $158-162 million. Cash from operations reached $37.2 million in the first nine months, with $72.0 million available cash as of September 30. Kamada expanded operations with a new plasma collection center in Houston, TX.
Kamada (NASDAQ: KMDA) announced it will release its Q3 and nine-months financial results for the period ended September 30, 2024, before U.S. markets open on November 13, 2024. The company will host an investment community conference call at 8:30am Eastern Time on the same day. Shareholders can participate by dialing specific numbers for U.S., Israel, and International access. The call will also be available via webcast.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, announced its participation in the Stifel 2024 Healthcare Conference in New York. CEO Amir London will deliver a corporate overview on November 18, 2024, at 10:55 a.m. ET. The event will be held from November 18-19, 2024. Investors can arrange one-on-one meetings through Stifel representatives, and a live webcast will be available on Kamada's website with a 30-day replay option.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA) has expanded its plasma collection operations by opening a new center in Houston, TX. The 12,000 square foot facility, operated by Kamada Plasma, is designed to support over 50 donor beds with an estimated annual collection capacity of 50,000 liters. It will collect both normal source plasma and specialty plasma, such as Anti-Rabies and Anti-D, and is expected to be one of the largest specialty plasma collection sites in the U.S.
The company plans to submit regulatory applications to the FDA and EMA in the first half of 2025 for approval of the Houston site. Kamada is also constructing a third plasma collection center in San Antonio, TX, set to open in the first half of 2025. Each center is projected to contribute annual revenues of $8 million to $10 million in sales of normal source plasma at full capacity.
Kamada reported strong financial results for Q2 and H1 2024. Revenues for Q2 2024 were $42.5 million, a 13% increase YoY, and $80.2 million for H1 2024, up 18% YoY. Q2 2024 adjusted EBITDA was $9.1 million, a 51% increase YoY, and $16.6 million for H1 2024, up 68% YoY. Net income for Q2 2024 was $4.4 million ($0.08 per share), and $6.8 million ($0.12 per share) for H1 2024. Kamada reiterated its full-year revenue guidance of $158-$162 million and adjusted EBITDA of $28-$32 million. Increased sales of KEDRAB and CYTOGAM in the US market were primary revenue drivers. Operating expenses rose due to higher S&M and R&D costs associated with marketing and the advanced Inhaled AAT clinical trial. Kamada generated $15.0 million of cash from operating activities in H1 2024 and held $56.5 million in cash and equivalents as of June 30, 2024. The company continues to explore new business opportunities and expects double-digit growth beyond 2024.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has announced its upcoming financial results release. The company will disclose its second quarter and first half 2024 financial results on August 14, 2024, before U.S. financial markets open.
Following the release, Kamada's management will host an investment community conference call at 8:30am Eastern Time on the same day. Shareholders and interested parties can participate via phone or webcast. The call will be archived on the company's website for 90 days.
Kamada reported strong first quarter 2024 financial results with a 23% increase in revenues and a 96% rise in profitability. The company's top-line growth was driven by U.S. sales of KEDRAB® and CYTOGAM®. Kamada increased its full-year revenue guidance to $158-162 million and adjusted EBITDA to $28-32 million. The company remains optimistic about its growth prospects beyond 2024.
Kamada will announce its first quarter 2024 financial results on May 8, 2024, before the U.S. financial markets open. The company, known for its rare condition treatments, will host an investment community conference call to discuss the results.